A mathematical model developed by NIH grantees predicts that women must take the antiretroviral medication Truvada daily to prevent HIV infection via vaginal sex. Whereas just two doses per week can protect men from HIV infection via anal sex. This finding helps explain why two large clinical trials testing HIV pre-exposure prophylaxis, or PrEP, in women failed to show efficacy. Participants in the VOICE and FEM-PrEP trials of Truvada and tenofovir ...
Read MoreYou have just read an article categorized health
titled Mathematical Model Explains Why HIV Prevention Dosing Differs by Sex.
Written by:
editor - Saturday, November 1, 2014
There are currently no comments for "Mathematical Model Explains Why HIV Prevention Dosing Differs by Sex"
Post a Comment